CINECA IRIS Institutional Research Information System

FERRERO, Simone
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.364
EU - Europa 3.527
AS - Asia 1.548
SA - Sud America 108
OC - Oceania 85
AF - Africa 42
Continente sconosciuto - Info sul continente non disponibili 4
Totale 9.678
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.256
IT - Italia 1.150
CN - Cina 622
IE - Irlanda 377
SE - Svezia 372
FR - Francia 268
KR - Corea 201
AT - Austria 197
DE - Germania 196
GB - Regno Unito 194
JP - Giappone 150
IN - India 109
UA - Ucraina 103
DK - Danimarca 100
TR - Turchia 99
FI - Finlandia 93
VN - Vietnam 92
ES - Italia 85
AU - Australia 76
CA - Canada 64
PL - Polonia 63
NL - Olanda 53
BE - Belgio 52
CH - Svizzera 47
GR - Grecia 46
SG - Singapore 46
BR - Brasile 45
TH - Thailandia 42
HK - Hong Kong 41
MX - Messico 36
PT - Portogallo 28
RU - Federazione Russa 28
NO - Norvegia 21
SN - Senegal 21
TW - Taiwan 21
CL - Cile 20
SA - Arabia Saudita 17
IL - Israele 16
IR - Iran 16
MY - Malesia 15
PE - Perù 14
PK - Pakistan 14
UZ - Uzbekistan 12
AR - Argentina 11
BY - Bielorussia 9
NZ - Nuova Zelanda 9
CO - Colombia 7
PH - Filippine 7
RO - Romania 7
CZ - Repubblica Ceca 6
BG - Bulgaria 5
ID - Indonesia 5
EC - Ecuador 4
EE - Estonia 4
EU - Europa 4
OM - Oman 4
PR - Porto Rico 4
SI - Slovenia 4
SK - Slovacchia (Repubblica Slovacca) 4
BD - Bangladesh 3
BO - Bolivia 3
EG - Egitto 3
HR - Croazia 3
HU - Ungheria 3
KW - Kuwait 3
KZ - Kazakistan 3
LT - Lituania 3
MA - Marocco 3
NG - Nigeria 3
PS - Palestinian Territory 3
RS - Serbia 3
VE - Venezuela 3
BH - Bahrain 2
DZ - Algeria 2
GH - Ghana 2
GT - Guatemala 2
LV - Lettonia 2
MU - Mauritius 2
SC - Seychelles 2
TN - Tunisia 2
AE - Emirati Arabi Uniti 1
CU - Cuba 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
IQ - Iraq 1
JO - Giordania 1
LU - Lussemburgo 1
MM - Myanmar 1
MN - Mongolia 1
UY - Uruguay 1
ZA - Sudafrica 1
Totale 9.678
Salva come PNG Salva come JPEG
Città #
Chandler 625
Dublin 373
Beijing 320
Torino 262
Fairfield 242
Ashburn 240
Vienna 193
Ann Arbor 191
Wilmington 152
Houston 148
Nyköping 144
Dearborn 117
Villeurbanne 116
Woodbridge 116
Medford 111
Princeton 94
Cambridge 93
Seattle 83
Florence 81
Redwood City 79
San Mateo 78
Turin 73
Jacksonville 71
Rome 70
Fremont 58
Milan 54
Dong Ket 49
Pisa 41
Washington 39
Boston 36
Sydney 36
Shanghai 35
Warsaw 32
Chennai 30
Guangzhou 29
New York 29
Brussels 27
Istanbul 26
Bologna 25
London 25
Hebei 23
Tokyo 23
Toronto 22
Barcelona 21
Hangzhou 20
Ankara 19
Chengdu 19
Nanjing 19
San Diego 19
Central 18
Norwalk 17
Bangkok 16
Berlin 16
Madrid 16
Singapore 16
Boardman 15
Melbourne 15
Philadelphia 15
Seoul 15
Guiyang 14
Lima 14
Oslo 14
São Paulo 14
Zurich 14
Athens 13
Atlanta 13
Helsinki 13
Los Angeles 13
Rochester 13
Newburyport 12
Taipei 12
Amsterdam 11
Bengaluru 11
Mountain View 11
Ottawa 11
Santiago 11
Zhengzhou 11
Genoa 10
Munich 10
Naples 10
Padova 10
Palermo 10
Paris 10
Pune 10
Duncan 9
Hefei 9
Lisbon 9
Liverpool 9
San Jose 9
Xian 9
Brisbane 8
Chicago 8
Diyarbakir 8
Falls Church 8
Frankfurt am Main 8
Hat Yai 8
Kuala Lumpur 8
Nagareyama 8
Polska 8
Redmond 8
Totale 5.416
Salva come PNG Salva come JPEG
Nome #
ABVD vs BEACOPP escalated in advanced-stage Hodgkin’s lymphoma: Results from a multicenter European study 1.016
Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi 910
HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data 373
Early progression as a predictor of survival in marginal zone lymphomas: An analysis from the FIL-NF10 study 343
Maternal and Perinatal Outcomes of Pregnant Women with SARS-COV-2 infection 270
Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma 246
Novel CALR somatic mutations in essential thrombocythaemia 225
Minimal residual disease in mantle cell lymphoma: are we ready for a personalized treatment approach? 225
Prospective molecular monitoring of minimal residual disease after nonmyeloablative allografting in newly diagnosed multiple myeloma 192
Highly sensitive MYD88 l265p mutation detection by droplet digital polymerase chain reaction in waldenström macroglobulinemia 186
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis 178
Centralized Biobanking Supports Hematology Clinical Trials: the new challenge of the University of Torino 174
A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the "Fondazione Italiana Linfomi" MCL-0208 trial 161
A 6-GENE EXPRESSION SIGNATURE IN MANTLE CELL LYMPHOMA: RESULTS FROM THE FONDAZIONE ITALIANA LINFOMI (FIL)-MCL-0208 TRIAL 151
Applying data warehousing to a phase III clinical trial from the Fondazione Italiana Linfomi (FIL) ensures superior data quality and improved assessment of clinical outcomes. 124
New Molecular Technologies for Minimal Residual Disease Evaluation in B-Cell Lymphoid Malignancies 121
High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma 120
High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma 114
Psychological distress and oral chemotherapy: a pilot study. 112
KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study 106
Ficoll-hypaque separation vs whole blood lysis: Comparison of efficiency and impact on minimal residual disease analysis 104
Characteristics of the Immunoglobulin Heavy Chain (IgH) Rearrangement in Multiple Myeloma (MM): An Analysis On 308 Cases 103
COMPREHENSIVE ANALYSIS OF BASELINE OUTCOME BIOPREDICTORS IN YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: THE ANCILLARY BIOLOGICAL STUDIES OF FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 CLINICAL TRIAL 97
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi 96
MYD88L265P MUTATION DETECTION IN WALDENSTRÖM MACROGLOBULINEMIA BY DROPLET DIGITAL PCR: MINIMAL RESIDUAL DISEASE MONITORING AND CHARACTERIZATION ON CIRCULATING FREE DNA 94
Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR 94
Delphi, a Data Warehouse to Discover Associations between Variables in Clinical Trials: Application to the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial 94
Correlation Between Clinical Outcome and Disease Kinetics by Quantitative PCR in Myeloma Patients Following Post-Transplant Consolidation with Bortezomib, Thalidomide and Dexamethasone 92
Droplet digital PCR for minimal residual disease detection in mature lymphoproliferative disorders 91
A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines 91
Telomere Length Is An Independent Predictor of Survival, Treatment Requirement and Richter’s Syndrome Transformation in Chronic Lymphocytic Leukemia 89
Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival 89
Telomere length is an independent predictor of survival, treatment requirement and Richter’s syndrome transformation in chronic lymphocytic leukemia 87
Italian real life experience with ibrutinib: Results of a large observational study on 77 relapsed/refractory mantle cell lymphoma 86
High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma 83
Expression of telomeric proteins in chronic lymphocytic leukemia (CLL) 82
The Engineered MIPI (e-MIPI), a Candidate Data-Mining Based Mantle Cell Lymphoma Prognostic Index Developed from the Dataset of the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial 81
Oral chemotherapy: an innovative choice 79
Droplet Digital PCR Assay for MYD88L265P 77
Real life use of bendamustine in elderly patients with lymphoid neoplasia 77
Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: Evidences from long term follow-up 76
Consolidation with Bortezomib, Thalidomide and Dexamethasone Induces Molecular Remissions in Autografted Multiple Myeloma Patients 75
LONG-TERM RESULTS of the GIMEMA VTD Consolidation TRIAL In Autografted MULTIPLE Myeloma PATIENTS (VEL-03-096): IMPACT of Minimal RESIDUAL DISEASE Detection by REAL Time Quantitative PCR On LATE Recurrences and Overall SURVIVAL 73
Major Shrinking of Residual Tumor Cell Burden and Achievement of Molecular Remissions in Myeloma Patients Undergoing Post-Trasplant Consolidation with Bortezomib, Thalidomide and Dexamethasone: A Qualitative and Quantitative PCR Study 71
Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network 71
MYC Rearranged Aggressive B-Cell Lymphomas: A Report on 100 Patients of the Fondazione Italiana Linfomi (FIL) 70
Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study 69
Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes 68
Minimal Residual Disease in Indolent Lymphomas: A Critical Assessment 68
Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders 67
Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia 67
Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia 66
Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death 65
null 64
A targeted mutational landscape of angioimmunoblastic T-cell lymphoma 64
PERSONALIZED MEDICINE IN LYMPHOMA: TAILORING TREATMENT ACCORDING TO MINIMAL RESIDUAL DISEASE 63
Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi 62
Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: Final results of a European MCL Network Phase II Trial 60
Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin’s lymphoma: evidence from a multicenter, retrospective study 60
Application of the Euro Clonality next-generation sequencing-based marker screening approach to detect immunoglobulin heavy chain rearrangements in mantle cell lymphoma patients: first data from the Fondazione Italiana Linfomi MCL0208 trial 58
Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells 57
A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL) 56
Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation 55
Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms 53
Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option? 53
COVID-19 in a Post-transplant Heart Recipient Who Developed Aggressive Lymphoma: A Biphasic Course During Rituximab Treatment 51
HIGH RATES OF PROLONGED MOLECULAR REMISSIONS AFTER TANDEM AUTOLOGOUS-NONMYELOABLATIVE ALLOGRAFTING IN NEWLY DIAGNOSED MYELOMA 49
Droplet digital PCR quantification of mantle cell lymphoma follow-up samples from four prospective trials of the european MCL network 49
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease 47
Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. 45
Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: A phase II clinical trial of the fondazione italiana linfomi 45
Mantle Cell Lymphoma of Mucosa-Associated Lymphoid Tissue 45
Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma 44
The challenge of treating elderly patients with mantle cell lymphoma 43
Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial 42
SYNDECAN-1 PROMOTES THE ANGIOGENIC PHENOTYPE OF MULTIPLE MYELOMA ENDOTHELIAL CELLS 41
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies 41
Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma 40
Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase III trial in mantle cell lymphoma 40
How to treat old MCL patients: One size fits it all? 38
MYD88L265P Detection in IgM Monoclonal Gammopathies: Methodological Considerations for Routine Implementation 38
Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma 37
Allogeneic stem cell transplantation in mantle cell lymphoma in the era of new drugs and CAR-T cell therapy 36
ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder 35
The role of targeted treatment in mantle cell lymphoma: Is transplant dead or alive? 34
A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi 34
The current therapeutic scenario for relapsed mantle cell lymphoma 31
Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study 31
Dissecting MRD Kinetics By Automated Computational Analysis to Improve Outcome Prediction in Mantle Cell Lymphoma: A Bioinformatic Substudy from the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial 30
Personalized medicine in lymphoma: Is it worthwhile? The mantle cell lymphoma experience 30
A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial 28
How to manage mantle cell lymphoma 26
Dichotomic response to interleukin-6 blockade in idiopathic multicentric Castleman disease: two case reports 24
Quality Assessment for PCR-based Minimal Residual Disease in Lymphoma: 10 Years of Cross-laboratory Standardization Process Within the Fondazione Italiana Linfomi MRD Network 23
HBV Reactivation in Patients with Past Infection Affected by Non-Hodgkin Lymphoma and Treated with Anti-CD20 Antibody Based Immuno-Chemotherapy: A Multicenter Experience 23
New paradigms in mantle cell lymphoma: Is it time to risk-stratify treatment based on the proliferative signature? 21
Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program 19
Efficacy of rituximab in anti-myelin-associated glycoprotein demyelinating polyneuropathy: Clinical, hematological and neurophysiological correlations during 2 years of follow-up 17
Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma. 16
Nucleic Acid Biomarkers in Waldenström Macroglobulinemia and IgM-MGUS: Current Insights and Clinical Relevance 16
Totale 9.953
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.765
article - articoli 0
book - libri 0
conference - conferenze 5.111
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.876
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019129 0 0 0 0 0 0 0 0 0 0 84 45
2019/20201.010 17 17 33 125 73 139 104 83 106 98 119 96
2020/20211.315 126 75 141 64 121 77 75 82 124 102 110 218
2021/20221.822 79 68 110 164 114 109 204 110 86 175 355 248
2022/20232.641 209 224 76 231 226 537 212 194 267 147 142 176
2023/20241.579 161 262 150 131 215 251 119 148 19 110 13 0
Totale 10.005